Discovering breakthroughs in fibrosis and neurodegeneration
Blade Therapeutics is advancing a differentiated pipeline of oral, small-molecule therapies that include a non-competitive autotaxin inhibitor and multiple inhibitors of dimeric calpains for the potential treatment of lung, liver and cardiac fibrosis or neurodegenerative diseases. Since the company’s founding in 2015, Blade has used a combination of in-house drug research and selective in-licensing to build a risk-diversified pipeline.
Our focused approach offers the potential to produce disease-modifying, life-saving therapies.
1 Autotaxin Inhibitor
2 Calpain Inhibitor
A Novel Calpain Inhibitor Compound Has Protective Effects on a Zebrafish Model of Spinocerebellar Ataxia Type 3
Robinson et al., Cells 2021, 10, 2592
Calpain 9 as a therapeutic target in TGFβ-induced mesenchymal transition and fibrosis
Kim et al., Sci. Transl. Med. 11, July 2019
Calpain 1 and 2 Are Required for RNA Replication of Echovirus 1
Upla et al., Journal of Virology 82, Feb 2008